Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAST-BOOSTER: Preoperative Pembrolizumab and Radiotherapy in Breast Cancer
NCT06472583Phase 2Recruiting
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Apr 2024
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Pembrolizumab Arm with Placebo Arm (2 arms). Primary endpoint: Pathological Complete Response. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06472583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472583.